A groundbreaking cancer detection study published in Cell [1] cites the use of HemaCare-sourced human bone marrow.
The Cell publication is part of a global collaborative effort based in 8 different countries, including several U.S. based cancer research institutes. Their goal is simple; find a way to detect cancer early, no matter where it originates in the human body, thereby securing the best possible chance of treating patients successfully.
Researchers have found that T Cells can target cells that are in a state of cellular senescence, without damaging the tissues while promoting a longer life span.
When a cell is in a state of cycle arrest and is stable in that cycle, it is considered cellular senescence. Senescent cells do not respond to growth-promoting signaling or stimuli and exhibit various biochemical changes leading to a phenotype characterized by altered gene expression and changes in cellular metabolism. The biological role of senescence is multifaceted and is important during embryonic development and wound healing. However, it is also involved in pathological processes such as cancer development and chronic inflammatory conditions.
Researchers at the University of California San Diego used natural killer cells in a study as immunotherapeutic agents. They found that the natural killer cells are effective in ridding tumor cells from the body.
Immunotherapy for cancer treatment is rapidly emerging, and many studies are aimed at increasing the safety and efficacy of anti-tumor immunotherapy. Although T cells have been extensively studied, more research is being conducted on the use of natural killer (NK) cells as immunotherapeutic agents. NK cells are lymphocytes of the immune system capable of attacking and killing virus-infected and tumor cells. NK cells can lyse tumor cells without prior activation, but the potency of this effect limits its clinical use.
The University of Oxford conducted clinical trials on a possible vaccine for SARS-CoV-2 and the results produce a positive immune response.
As the race for a COVID (SARS-CoV-2) vaccine forges ahead across the globe, some scientists are obtaining clinical trial results that suggest progress toward an effective vaccine. Results of clinical trials conducted by scientists at the University of Oxford suggest that their newly developed vaccine elicits expected immune responses with an acceptable safety profile. Two immunity responses, antibody production, and T cell response to infected cells were assessed in the clinical trial participants.
New studies have found that people who have tested negative for COVID-19 antibodies, developed T cells instead in a response to their COVID-19 infections.
When the body is infected with a pathogen such as a virus, it mounts a protective response through immune cells and the production of pathogen-specific antibodies. The antibodies remove the viruses before they can infect cells. Cytotoxic T cells kill infected cells via inflammatory mediators to prevent the function of the invading organism. In the case of COVID-19 (SARS-CoV-2) clinical studies, patients have been found to recover from the viral infection without the development of antibodies to the virus. However, they did develop a T-cell response to COVID-19. Therefore, it is believed that people who are asymptomatic or have a mild illness can remove the virus via T cells.